FDA Accepts Dyne's BLA for DMD Drug, Grants Priority Review with Jan 2027 PDUFA
DYN has more than doubled off its 52-week low of $8.88.
Summary
The FDA accepted Dyne's BLA for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, setting a PDUFA date of January 21, 2027. This follows the BLA submission in May and full enrollment of the registrational cohort in June. Priority Review signals the FDA sees this as a potential significant advance, and the company expects a U.S. launch in Q1 2027 if approved. With shares near a 52-week high, the market has been pricing in regulatory progress, but the official acceptance and timeline remove uncertainty and bring a near-term catalyst into focus.
At the time of this announcement, DYN was trading at $23.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $8.88 to $25.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.